Global Biosimulation Market is expected to reach USD XX Billion by 2026 from USD 1.61 Billion in 2019 at CAGR of XX % (Detailed analysis of the market CAGR is provided in the report). The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region. Global Biosimulation Market is segmented by product & services, delivery mode, application, end user, and geography. Biosimulation Software segment is expected to register highest growth in forecast period. Growing adoption of biosimulation software by pharmaceutical and research organizations will fuel the Biosimulation Software segment growth. Delivery mode segment is classified as subscription and ownership model. Subscription model sub segment is estimated to hold the largest market share in forecast period. Subscription model provides various advantages such as cost-effectiveness, interoperability, and flexibility these will result into increasing share of subscription model market. The market on the basis of geography is segmented by North America, Europe, Asia-Pacific, Middle East & Africa and Latin America. Increase in R&D investments in the pharmaceutical and biotechnology industries are trending the overall Global Biosimulation market. Issues related to lack of standardization may hamper the market growth. North America is going to emerge as one of the higher growth region in forecast period followed by APAC and Europe. Growth in the biotechnology and pharmaceutical industry, a large number of ongoing drug development processes will fuel the Biosimulation Market in North America region. Key Highlights: • Assessment of market definition along with the identification of key players and analysis of their strategies to determine the competitive outlook of the market, opportunities, drivers, restraints and challenges for this market during the forecast period • Complete quantitative analysis of the industry from 2019 to 2026 to enable the stakeholders to capitalize on the prevailing market opportunities • In-depth analysis of the industry on the basis of market segments, market dynamics, market size, competition & companies involved value chain • Global Biosimulation Market analysis and comprehensive segmentation with respect to the product & services, delivery mode, application, end user, and geography to assist in strategic business planning • Global Biosimulation Market analysis and forecast for five major geographies North America, Europe, Asia pacific, Middle East & Africa, Latin America and their key regions Research Methodology Bloomberg, Hoovers, and Factiva are some of the sites that are being referred to gain insights about Global Biosimulation Market. Experts from top manufacturing companies along with other stakeholders have been considered. This is done to validate and collect critical information for evaluating trends related to this market during the forecast period. Top-down and bottom-up approaches have been used to estimate the global and regional size of this market. Data triangulation techniques along with other comparative analysis are also used to calculate the exact size of the Global Biosimulation Market globally. Key Players in the Global Biosimulation Market Are: • Inosim Software • Nuventra Pharma • Insilico Biotechnology • Leadinvent Technologies • In Silico Biosciences • Evidera • Physiomics • Genedata • Rosa • Chemical Computing Group • Advanced Chemistry Development • Schrödinger • Dassault Systèmes • Simulation Plus • Certara Key Target Audience: • Venture Capitalists, Private Equity Firms, And Startup Companies • Contract research organizations (CROs) • Market research and consulting companies • Biotechnology and pharmaceutical companies • Regulatory authorities • Biosimulation product manufacturers, vendors, and distributors • Government Bodies And Healthcare Associations/Institutions Scope of the Report: Research report categorizes the Global Biosimulation Market based on product & services, delivery mode, application, end user, and geography (region wise). Market size by value is estimated and forecasted with the revenues of leading companies operating in the Global Biosimulation Market with key developments in companies and market trends. Global Biosimulation Market, By Delivery Mode • Subscription Models • Ownership Models Global Biosimulation Market, By Product & Services • Software • Services Global Biosimulation Market, By Application • Drug Development • Drug Discovery • Other Application Global Biosimulation Market, By End User • Pharmaceutical and Biotechnology Companies • Research Institutes • Contract Research Organizations • Regulatory Authorities • Other End Users Global Biosimulation Market, By Geography: • North America • Europe • Asia Pacific • Middle East & Africa • Latin America Available Customization Maximize Market Research offers customization of the report and scope of the report as per the specific requirement of our client.
Table of Contents
1. EXECUTIVE SUMMARY 2. RESEARCH METHODOLOGY 2.1. Market Definition 2.2. Market Scope 2.3. Data Sources 3. MARKET DYNAMICS 3.1. Market Drivers 3.2. Market Restraints 3.3. Market Opportunities 4. END-USER OVERVIEW 4.1. Value Chain Analysis 4.2. Key Trends 5. GLOBAL BIOSIMULATION MARKET, BY DELIVERY MODE (2019-2026) 5.1. Introduction 5.2. Subscription Models 5.2.1. Subscription Models Market Overview 5.2.2. Subscription Models Market Size & Forecast 5.3. Ownership Models 5.3.1. Ownership Models Market Overview 5.3.2. Ownership Models Market Size & Forecast 6. GLOBAL BIOSIMULATION MARKET, BY PRODUCT & SERVICES (2019-2026) 6.1. Introduction 6.2. Software 6.2.1. Software Market Overview 6.2.2. Software Market Size & Forecast 6.3. Services 6.3.1. Services Market Overview 6.3.2. Services Market Size & Forecast 7. GLOBAL BIOSIMULATION MARKET, BY APPLICATION (2019-2026) 7.1. Introduction 7.2. Drug Development 7.2.1. Drug Development Market Overview 7.2.2. Drug Development Market Size & Forecast 7.3. Drug Discovery 7.3.1. Drug Discovery Market Overview 7.3.2. Drug Discovery Market Size & Forecast 7.4. Other Application 7.4.1. Other Application Market Overview 7.4.2. Other Application Market Size & Forecast 8. GLOBAL BIOSIMULATION MARKET, BY END USER (2019-2026) 8.1. Introduction 8.2. Pharmaceutical and Biotechnology Companies 8.2.1. Pharmaceutical and Biotechnology Companies Market Overview 8.2.2. Pharmaceutical and Biotechnology Companies Market Size & Forecast 8.3. Research Institutes 8.3.1. Research Institutes Market Overview 8.3.2. Research Institutes Market Size & Forecast 8.4. Contract Research Organizations 8.4.1. Contract Research Organizations Market Overview 8.4.2. Contract Research Organizations Market Size & Forecast 8.5. Regulatory Authorities 8.5.1. Regulatory Authorities Market Overview 8.5.2. Regulatory Authorities Market Size & Forecast 8.6. Other End Users 8.6.1. Other End Users Market Overview 8.6.2. Other End Users Market Size & Forecast 9. GLOBAL BIOSIMULATION MARKET, BY GEOGRAPHY (2019-2026) 9.1. North America Biosimulation Market 9.1.1. North America Biosimulation Market, By Product and Services 9.1.2. North America Biosimulation Market, By Delivery Mode 9.1.3. North America Biosimulation Market, By Application 9.1.4. North America Biosimulation Market, By End User 9.1.5. North America Biosimulation Market, by Region 126.96.36.199. U.S. Biosimulation Market 188.8.131.52. Canada Biosimulation Market 184.108.40.206. Mexico Biosimulation Market 9.2. Europe Biosimulation Market 9.2.1. Europe Biosimulation Market, By Product and Services 9.2.2. Europe Biosimulation Market, By Delivery Mode 9.2.3. Europe Biosimulation Market, By Application 9.2.4. Europe Biosimulation Market, By End User 9.2.5. Europe Biosimulation Market, by Region 220.127.116.11. France Biosimulation Market 18.104.22.168. Germany Biosimulation Market 22.214.171.124. U.K. Biosimulation Market 126.96.36.199. Italy Biosimulation Market 188.8.131.52. Spain Biosimulation Market 184.108.40.206. Rest of Europe Biosimulation Market 9.3. Asia Pacific Biosimulation Market 9.3.1. Asia-Pacific Biosimulation Market, By Product and Services 9.3.2. Asia-Pacific Biosimulation Market, By Delivery Mode 9.3.3. Asia-Pacific Biosimulation Market, By Application 9.3.4. Asia-Pacific Biosimulation Market, By End User 9.3.5. Asia-Pacific Biosimulation Market, by Region 220.127.116.11. China Biosimulation Market 18.104.22.168. Japan Biosimulation Market 22.214.171.124. India Biosimulation Market 126.96.36.199. South Korea Biosimulation Market 188.8.131.52. Rest of Asia Pacific Biosimulation Market 9.4. Middle East & Africa Biosimulation Market 9.4.1. Middle East & Africa Biosimulation Market, By Product and Services 9.4.2. Middle East & Africa Biosimulation Market, By Delivery Mode 9.4.3. Middle East & Africa Biosimulation Market, By Application 9.4.4. Middle East & Africa Biosimulation Market, By End User 9.4.5. Middle East & Africa Biosimulation Market, by Region 184.108.40.206. South Africa Biosimulation Market 220.127.116.11. Rest of Middle East and Africa Biosimulation Market 9.5. Latin America Biosimulation Market 9.5.1. Latin America Biosimulation Market, By Product and Services 9.5.2. Latin America Biosimulation Market, By Delivery Mode 9.5.3. Latin America Biosimulation Market, By Application 9.5.4. Latin America Biosimulation Market, By End User 9.5.5. Latin America Biosimulation Market, by Region 18.104.22.168. Brazil Biosimulation Market 22.214.171.124. Rest of Latin America Biosimulation Market 10. MARKET COMPETITION ANALYSIS 10.1 Market Share/Positioning Analysis 10.2 Key Innovators 10.3 Company Profiles 10.3.1 Inosim Software 10.3.1.1 Overview 10.3.1.2 Products/ End-User 10.3.1.3 Strategy 10.3.1.4 Key Developments 10.3.2 Nuventra Pharma 10.3.2.1 Overview 10.3.2.2 Products/ End-User 10.3.2.3 Strategy 10.3.2.4 Key Developments 10.3.3 Insilico Biotechnology 10.3.3.1 Overview 10.3.3.2 Products/ End-User 10.3.3.3 Strategy 10.3.3.4 Key Developments 10.3.4 Leadinvent Technologies 10.3.4.1 Overview 10.3.4.2 Products/ End-User 10.3.4.3 Strategy 10.3.4.4 Key Developments 10.3.5 In Silico Biosciences 10.3.5.1 Overview 10.3.5.2 Products/ End-User 10.3.5.3 Strategy 10.3.5.4 Key Developments 10.3.6 Evidera 10.3.6.1 Overview 10.3.6.2 Products/ End-User 10.3.6.3 Strategy 10.3.6.4 Key Developments 10.3.7 Physiomics 10.3.7.1 Overview 10.3.7.2 Products/ End-User 10.3.7.3 Strategy 10.3.7.4 Key Developments 10.3.8 Genedata 10.3.8.1 Overview 10.3.8.2 Products/ End-User 10.3.8.3 Strategy 10.3.8.4 Key Developments 10.3.9 Rosa 10.3.9.1 Overview 10.3.9.2 Products/ End-User 10.3.9.3 Strategy 10.3.9.4 Key Developments 10.3.10 Chemical Computing Group 10.3.10.1 Overview 10.3.10.2 Products/ End-User 10.3.10.3 Strategy 10.3.10.4 Key Development 10.3.11 Advanced Chemistry Development 10.3.11.1 Overview 10.3.11.2 Products/ End-User 10.3.11.3 Strategy 10.3.11.4 Key Development 10.3.12 Schrödinger 10.3.12.1 Overview 10.3.12.2 Products/ End-User 10.3.12.3 Strategy 10.3.12.4 Key Development 10.3.13 Dassault Systèmes 10.3.13.1 Overview 10.3.13.2 Products/ End-User 10.3.13.3 Strategy 10.3.13.4 Key Development 10.3.14 Simulation Plus 10.3.14.1 Overview 10.3.14.2 Products/ End-User 10.3.14.3 Strategy 10.3.14.4 Key Development 10.3.15 Certara 10.3.15.1 Overview 10.3.15.2 Products/ End-User 10.3.15.3 Strategy 10.3.15.4 Key Development